Coherus Oncology, Inc. CHRS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -132.13M | -- | -- | -- | -118.02M |
| Total Depreciation and Amortization | 3.61M | -- | -- | -- | 3.63M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.06M | -- | -- | -- | 51.29M |
| Change in Net Operating Assets | -49.45M | -- | -- | -- | 3.87M |
| Cash from Operations | -186.03M | -- | -- | -- | -59.23M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.78M | -- | -- | -- | -17.58M |
| Cash from Investing | -9.78M | -- | -- | -- | -17.58M |
| Total Debt Issued | -- | -- | -- | -- | -141.00K |
| Total Debt Repaid | -121.00K | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 61.91M | -- | -- | -- | 241.00K |
| Repurchase of Common Stock | -115.00K | -- | -- | -- | -284.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 142.00K | -- | -- | -- | -16.00K |
| Cash from Financing | 61.82M | -- | -- | -- | -200.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -133.99M | -- | -- | -- | -77.02M |